Copyright
©The Author(s) 2024.
World J Clin Oncol. Dec 24, 2024; 15(12): 1468-1480
Published online Dec 24, 2024. doi: 10.5306/wjco.v15.i12.1468
Published online Dec 24, 2024. doi: 10.5306/wjco.v15.i12.1468
Figure 1 Median survival rates in the selected population.
A: Progression-free survival; B: Overall survival.
Figure 2 Median overall survival rates according to stratification factors.
A: Median overall survival (OS) in the smoking subgroup; B: Median OS in the alcohol consumption subgroup; C: Median OS in the body mass index subgroup. OS: Overall survival; BMI: Body mass index.
Figure 3 Median progression-free survival rates according to stratification parameters.
A: Median progression-free survival (PFS) in the smoking group; B: Median PFS in the alcohol consumption subgroup; C: Median PFS in the body mass index subgroup. PFS: Progression-free survival; BMI: Body mass index.
- Citation: Fasano M, Pirozzi M, Vitale P, Damiano V, Ronzino G, Farese S, Carfora V, Ciccarelli G, Di Giovanni I, Facchini S, Cennamo G, Caraglia M, Ciardiello F, Addeo R. Paclitaxel for second-line treatment of squamous cell carcinoma of the head and neck: A multicenter retrospective Italian study. World J Clin Oncol 2024; 15(12): 1468-1480
- URL: https://www.wjgnet.com/2218-4333/full/v15/i12/1468.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i12.1468